Skip to main content

Table 4 Comparative analysis of children exposed to tenofovir and zidovudine at CAISM/UNICAMP from 2000 to 2015

From: Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study

Variables

TDF

AZT

p*

RR

CI 95%

n

%

n

%

Gestational age (Capurro)

    

0.8962

  

 <37 weeks

8

21.1

153

22

 

0.95

0.44–2.03

 >=37 weeks

30

78.9

544

78

 

1

 

Birth weight

    

0.5221

  

 <2500 g

7

17.9

158

22.3

 

0.77

0.35–1.72

 >=2500 g

32

82.1

550

77.7

 

1

 

Weight adequacy for GA

    

0.3722

1

 

 Adequate for GA

28

73.7

563

80.3

 

1.29

0.60–2.76

 Small for GA

8

21.1

123

17.5

 

2.48

0.64–9.59

 Large for GA

2

5.3

15

2.1

   

5th minute Apgar

    

1.000**

  

 <7

0

0

5

0.7

   

 >=7

38

100

701

99.3

   

Neonatal disease

    

0.0056

  

 Yes

18

46.2

179

25.9

 

2.32

1.26–4.26

 No

21

53.8

512

74.1

 

1

 

Birth defect

    

0.0547**

  

 Yes

8

20

69

9.7

 

2.19

1.04–4.57

 No

32

80

641

90.3

 

1

 

Anemia

    

0.0030

  

 Yes

2

5.3

174

26.9

 

0.16

0.04–0.66

 No

36

94.7

473

73.1

 

1

 

Thrombocytopenia

    

0.6474**

  

 Yes

2

5.1

23

3.5

 

1.43

0.36–5.60

 No

37

94.9

624

96.5

 

1

 

Hepatic changes

    

0.0411

  

 Yes

19

51.4

101

34.2

 

1.86

1.02–3.41

 No

18

48.6

194

65.8

 

1

 

TOTAL

40

 

710

    
  1. GA gestational age, TDF tenofovir, AZT zidovudine
  2. (#) The numbers are different due to lack of information about some patients
  3. (##) Not calculated
  4. *Chi-square, **Fisher Exact